Clinical trials: Hormone Replacement Therapy
Pancreatic Adenocarcinoma
Pancreaze (Pancrelipase) for Patients With Pancreatic Adenocarcinoma With Cachexia and Exocrine Pancreatic Insufficiency
The objective of this study is to assess weight stability, functional changes, and quality of life when Pancreaze (pancrelipase) delayed-release 84,000-lipase units (capsules), for main meals, and 42,000-lipase units (capsules)…
- Trial name
- PANCAX-3 (NCT04098237)
- Testing
- Pancrelipase
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Andrew Hendifar, MD
Smoking, Smoking Cessation
Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients
The purpose of this study is to learn if a mindfulness-based smoking cessation smartphone app can help people quit smoking and stay on antiretroviral therapies.
- Conditions
- Smoking, Smoking Cessation, HIV
- Trial name
- NCT03999411
- Testing
- Nicoderm C-Q Transdermal Product, Adherence to Antiretroviral Therapy Counseling, Behavioral Smoking Cessation Counseling
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Miami
MPS 7, Sly Syndrome
A Phase 3 Study of UX003 Recombinant Human Betaglucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7)
The Phase 3 study will use a novel randomized, intra-subject placebo-controlled, single crossover design, referred to as Blind Start, to evaluate the safety and efficacy of UX003.
- Conditions
- MPS 7, Sly Syndrome, Mucopolysaccharidosis, MPS VII
- Trial name
- NCT02230566
- Testing
- UX003
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Ultragenyx Pharmaceutical Inc
Tobacco Use Cessation, Smoking Cessation
Implementation of HIT-Enhanced Tobacco Treatment for Hospitalized Smokers
This study will implement and test the effectiveness and cost-effectiveness of a tobacco cessation intervention (Academic Detailing + Integrated Tobacco Order Set - AD + ITOS) for adults admitted to the hospital.
- Conditions
- Tobacco Use Cessation, Smoking Cessation, Smoking, Tobacco Use Disorder
- Trial name
- NCT01691105
- Testing
- AD + Integrated Tobacco Order Set
- Where
- United States
- Volunteers
- 1,044 people
- Sponsor
- Yale University
Smoking, Smoking Cessation
A Novel Treatment to Boost Quit Attempts and Cessation Among Unmotivated Smokers
A sample of smokers who have no current plans to quit will be recruited for this study and randomized to one of two intervention conditions: 1. Practice Quit Attempt (PQA) aided by brief advice and self-help materials, or 2.
- Trial name
- NCT00706979
- Testing
- Practice Quit Attempt plus nicotine lozenge, Practice Quit Attempt only
- Volunteers
- 849 people
- Sponsor
- Medical University of South Carolina
Iron Deficiency Anemia, Iron Deficiency Anaemia
An Extension Trial to Assess the Safety of Re-dosing of Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monoferric®)
Evaluate safety and efficacy of intravenous (IV) iron isomaltoside/ferric derisomaltose re-dosing, in subjects who were previously treated with iron isomaltoside/ferric derisomaltose.
- Trial name
- FERWON-EXT (NCT02962648)
- Testing
- Iron isomaltoside/ferric derisomaltose
- Where
- 22 sites in United States
- Volunteers
- 103 people
- Sponsor
- Pharmacosmos A/S
Nicotine Dependence
Nicotine Replacement Therapy (NRT) and Bupropion Mechanisms of Effectiveness in Smokers
The purpose of this study is to better characterize differences in mood, attention, brain activation patterns underlying the beneficial effects of pharmacological treatments previously demonstrated to be help individuals…
- Trial name
- NCT01048944
- Testing
- Bupropion SR, Nicotine Patch
- Where
- United States
- Volunteers
- 197 people
- Sponsor
- Southern Illinois University Carbondale
Hunter Syndrome
An Observational Study Evaluating Anti-Idursulfase Serum Antibody Response in Hunter Syndrome Patients
The objective of this study is to evaluate the effect of anti-idursulfase antibodies on idursulfase safety (measured by infusion related adverse events) between patients who develop anti-idursulfase antibodies and patients who do…
- Trial name
- NCT00882921
- Testing
- Idursulfase
- Where
- 6 sites in United States, Brazil and 1 more
- Volunteers
- 26 people
- Sponsor
- Shire
Smoking Cessation
Telephone Counseling and the Distribution of Nicotine Patches to Smokers
The primary purpose of this study is to determine the effects of distributing free nicotine replacement therapy (NRT) to tobacco quitline callers directly. Specifically, this study aims to: 1.
- Trial name
- NCT00851357
- Testing
- Nicotine Patch, Telephone Counseling, Self-Help Materials
- Where
- United States
- Volunteers
- 4,200 people
- Sponsor
- University of California, San Diego
Smoking
Youth Smoking Cessation: Therapy +/- "The Patch"
Reducing tobacco use by adolescents is a national health priority. In recent polls, most adolescent smokers reported having tried unsuccessfully to quit.
- Trial name
- NCT00631020
- Testing
- CBME, Optional NRT
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Atherosclerosis
ELITE: Early Versus Late Intervention Trial With Estradiol
The purpose of this study is to examine the effects of oral 17B-estradiol (estrogen) on the progression of early (subclinical) atherosclerosis and cognitive decline in healthy postmenopausal women.
- Trial name
- NCT00114517
- Testing
- 17B-estradiol
- Where
- United States
- Volunteers
- 643 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Gaucher Disease
Multicenter Extension Study of Velaglucerase Alfa in Japanese Patients With Gaucher Disease
Gaucher disease is an inherited deficiency of the lysosomal enzyme glucocerebrosidase (GCB) that leads to progressive accumulation of glucocerebroside within macrophages and subsequent tissue and organ damage; typically of the…
- Trial name
- NCT01842841
- Testing
- velaglucerase alfa
- Where
- 5 sites in Japan
- Volunteers
- 5 people
- Sponsor
- Shire
Transgenderism
Transgender Estradiol Affirming Therapy
The purpose of this open label, pilot, randomized clinical trial is to evaluate the effectiveness, safety and tolerability of estrogen use in transgender female and the degree of testosterone suppression achieved in this…
- Trial name
- TREAT (NCT05010707)
- Testing
- Transdermal patch, Pro-thrombotic markers, Metabolic markers
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF)
OPTION: A Trial to Assess the Safety & Efficacy of MS1819 in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
The primary objectives of this study are to assess the safety and efficacy of MS1819-SD vs porcine pancreatic enzyme replacement therapy (PERT) in patients with exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF).
- Trial name
- OPTION (NCT03746483)
- Testing
- MS1819, Porcine PERT
- Where
- 14 sites in United States, Poland
- Volunteers
- 41 people
- Sponsor
- Entero Therapeutics
Smoking Cessation, Electronic Cigarette Use
CAN-DOSE Study: Cessation With Augmented Nicotine for Dual Use Of Smoking and E-cigarettes
Many people smoke cigarettes and use e-cigarettes, and have a hard time stopping. Nicotine replacement therapy medications, such as nicotine patches and lozenges, have been shown to help people quit e-cigarette use.
- Conditions
- Smoking Cessation, Electronic Cigarette Use, Cigarette Smoking
- Trial name
- CAN-DOSE (NCT06087328)
- Testing
- Regular Nicotine patch and lozenge dose, Augmented Nicotine patch and lozenge dose
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Medical University of South Carolina
SMA - Spinal Muscular Atrophy, Gene Therapy
Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1
Phase 3 pivotal US trial studying open-label intravenous administration of onasemnogene abeparvovec-xioi in spinal muscular atrophy (SMA) Type 1 participants.
- Trial name
- STR1VE (NCT03306277)
- Testing
- Onasemnogene Abeparvovec-xioi
- Where
- 16 sites in United States
- Volunteers
- 22 people
- Sponsor
- Novartis Gene Therapies
Growth Hormone Deficiency, Pediatric, Endocrine System Diseases
A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical Trial
A multicenter, phase 3, long-term extension trial of TransCon hGH administered once-weekly in children with growth hormone deficiency (GHD) who previously participated in a phase 3 TransCon hGH trial.
- Conditions
- Growth Hormone Deficiency, Pediatric, Endocrine System Diseases, Hormone Deficiency, Pituitary Diseases
- Trial name
- enliGHten (NCT03344458)
- Testing
- TransCon hGH
- Where
- 42 sites in United States, Armenia and 9 more
- Volunteers
- 298 people
- Sponsor
- Ascendis Pharma A/S
Primary Immune Deficiency Disorder
Follow-up Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)
The objective of this study is to assess the long-term safety, tolerability, and efficacy of IgPro20 in subjects with primary immunodeficiency (PID) as a follow-up to the pivotal study ZLB06_002CR (NCT01199705).
- Trial name
- NCT01458171
- Testing
- Immune globulin subcutaneous (Human)
- Where
- 9 sites in Japan
- Volunteers
- 23 people
- Sponsor
- CSL Behring
Nicotine Addiction, Smoking Cessation
e-Cigarettes Versus NRT Gum for Smoking Cessation
This is a randomized trial comparing electronic cigarettes (e-Cigarettes) to nicotine gum for smoking cessation. Participants will be randomly assigned to either e-cigarette use or nicotine gum use during a quit attempt.
- Trial name
- NCT01925781
- Testing
- Nicotine polacrilex, STAM 1100mAh CE4 eGo Clearomizer
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Creighton University
Fabry Disease
Safety and Efficacy of PRX-102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa)
This is an open label switch over study to assess the safety and efficacy of PRX-102 (pegunigalsidase alfa). Patients treated with agalsidase alfa for at least 2 years and on a stable dose (>80% labelled dose/kg) for at least 6…
- Trial name
- NCT03018730
- Testing
- PRX-102 (pegunigalsidase alfa)
- Where
- 9 sites in Australia, Canada and 5 more
- Volunteers
- 22 people
- Sponsor
- Protalix